p53 anticorps (AA 32-79)

N° du produit ABIN5646913

L’anticorps Souris Monoclonal anti-p53 a été validé pour WB, IF, FACS et IHC (p). Il convient pour détecter p53 dans des échantillons de Humain.

Aperçu rapide pour p53 anticorps (AA 32-79) (ABIN5646913)

Antigène: p53 (TP53) (Tumor Protein P53 (TP53))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp p53 est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: PAb 1801

Détail du produit anti-p53 anticorps

Épitope: AA 32-79

Aucune reactivité croisée: Souris, Rat (Rattus)

Attributs du produit: This mAb reacts with an N-terminal epitope (aa 32-79) of both wild type and mutated p53. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. In most transformed and tumor cells the concentration of p53 is increased 5-1000 fold over the minute concentrations (1000 Molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). It localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Mutations arise with an average frequency of 70 % but incidence varies from zero in carcinoid lung tumors to 97 % in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation. Positive nuclear staining with specific antibody has been reported to be a negative prognostic factor in breast carcinoma, lung carcinoma, colorectal, and urothelial carcinoma. Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma as well as to detect intratubular germ cell neoplasia.

Purification: Purified

Pureté: Protein G affinity chromatography

Immunogène: Human p53 beta-galactosidase fusion protein was used as the immunogen for this antibody. Its epitope maps near the N-terminal end (aa 32-79) of p53.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Variations in protocols, secondaries and substrates may require the p53 antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 0.5-1 μg/mL,FACS: 0.5-1 μg/million cells,Immunofluorescence: 1-2 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store the p53 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur p53

Antigène: p53 (TP53) (Tumor Protein P53 (TP53))

Autre désignation: p53 / TP53

Sujet: This mAb reacts with an N-terminal epitope (aa 32-79) of both wild type and mutated p53. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. In most transformed and tumor cells the concentration of p53 is increased 5-1000 fold over the minute concentrations (1000 Molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). It localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Mutations arise with an average frequency of 70 % but incidence varies from zero in carcinoid lung tumors to 97 % in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation. Positive nuclear staining with specific antibody has been reported to be a negative prognostic factor in breast carcinoma, lung carcinoma, colorectal, and urothelial carcinoma. Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma as well as to detect intratubular germ cell neoplasia.

Pathways: Signalisation p53, Signalisation MAPK, Signalisation PI3K-Akt, Apoptose, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy, L'effet Warburg